{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:44:02Z","timestamp":1792629842625,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to clarify the role of LINC00907 in hepatocellular carcinoma (HCC) and its underlying molecular mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The research population comprised 117 participants diagnosed with HCC. The expressions of LINC00907 and miR-24-3p in both tissue specimens and cell lines, along with those of EMT markers and the MMP-2 and MMP-9, were measured using RT-qPCR. Cellular proliferation was measured with the CCK-8 assay, while apoptotic rates were determined by flow cytometry. The direct interactions between LINC00907, miR-24-3p, and PDGFRL were validated by dual luciferase reporter and RNA pull-down assays. HCC cells were transfected with constructs specifically modulating LINC00907 and miR-24-3p to investigate the impact of their expression on malignant phenotypic behaviors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LINC00907 expression was significantly downregulated in HCC, whereas miR-24-3p expression was upregulated. Low LINC00907 expression was linked to significantly worse overall survival, as determined by Kaplan-Meier analysis. The upregulation of LINC00907 led to the suppression of cell proliferation and EMT, while inducing apoptosis and reducing the levels of MMP-2 and MMP-9. LINC00907 was shown to directly target and negatively regulate miR-24-3p. Furthermore, rescue experiments demonstrated that upregulation of miR-24-3p counteracted the tumor-suppressive effects mediated by LINC00907 overexpression in HCC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LINC00907 exerts tumor-suppressive effects by targeting and negatively regulating miR-24-3p, thereby influencing proliferation, apoptosis, and EMT in HCC cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-026-00714-6","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:30:00Z","timestamp":1784809800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["LINC00907 suppresses malignant progression in hepatocellular carcinoma by inhibiting miR-24-3p"],"prefix":"10.1186","volume":"163","author":[{"given":"Jihua","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"6","key":"714_CR1","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/hep.32447","volume":"75","author":"F Foerster","year":"2022","unstructured":"Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: a guide for hepatologists. Hepatology. 2022;75(6):1604\u201326.","journal-title":"Hepatology"},{"issue":"1","key":"714_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2023.06.004","volume":"33","author":"NE Rich","year":"2024","unstructured":"Rich NE. Changing epidemiology of hepatocellular carcinoma within the United States and worldwide. Surg Oncol Clin N Am. 2024;33(1):1\u201312.","journal-title":"Surg Oncol Clin N Am"},{"issue":"11","key":"714_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400062","volume":"3","author":"W Gu","year":"2024","unstructured":"Gu W, de L\u00e9dinghen V, Aub\u00e9 C, Krag A, Strassburg C, Cast\u00e9ra L, et al. Hepatocellular cancer surveillance in patients with advanced chronic liver disease. NEJM Evid. 2024;3(11):EVIDoa2400062.","journal-title":"NEJM Evid"},{"issue":"12","key":"714_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41575-024-00967-4","volume":"21","author":"LY Mak","year":"2024","unstructured":"Mak LY, Liu K, Chirapongsathorn S, Yew KC, Tamaki N, Rajaram RB, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol. 2024;21(12):834\u201351.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"714_CR5","doi-asserted-by":"crossref","unstructured":"Li C, Hu J, Li M, Mao Y, Mao Y. Integrated multi-omics analysis and machine learning refine molecular subtypes and clinical outcome for hepatocellular carcinoma. Hereditas. 2025;162(1):61.","DOI":"10.1186\/s41065-025-00431-6"},{"issue":"1","key":"714_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02298-9","volume":"21","author":"Z Wang","year":"2021","unstructured":"Wang Z, Wen P, Hu B, Cao S, Shi X, Guo W, et al. Dopamine and dopamine receptor D1 as a novel favourable biomarker for hepatocellular carcinoma. Cancer Cell Int. 2021;21(1):586.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"714_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s41065-025-00509-1","volume":"162","author":"F Yu","year":"2012","unstructured":"Yu F, Yin S, Zhu J, Sun K. Research landscape of photodynamic therapy for hepatocellular carcinoma: hotspots and prospects from 2012 to 2025. Hereditas. 2012;162(1):174.","journal-title":"Hereditas"},{"key":"714_CR8","doi-asserted-by":"crossref","unstructured":"Zhang Y. LncRNA-encoded peptides in cancer. J Hematol Oncol. 2024;17(1):66.","DOI":"10.1186\/s13045-024-01591-0"},{"issue":"2","key":"714_CR9","first-page":"1121","volume":"20","author":"G Li","year":"2019","unstructured":"Li G, Shi H, Wang X, Wang B, Qu Q, Geng H, et al. Identification of diagnostic long non\u2011coding RNA biomarkers in patients with hepatocellular carcinoma. Mol Med Rep. 2019;20(2):1121\u201330.","journal-title":"Mol Med Rep"},{"issue":"1","key":"714_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49358-w","volume":"13","author":"L Liu","year":"2023","unstructured":"Liu L, Tang H, Wang K, Liu J, Luo N, Jin G. A three-gene signature reveals changes in the tumor immune microenvironment in the progression from NAFLD to HCC. Sci Rep. 2023;13(1):22295.","journal-title":"Sci Rep"},{"issue":"8","key":"714_CR11","first-page":"6868","volume":"16","author":"G Du","year":"2024","unstructured":"Du G, Jiang Z, Xia T, Liu M, Liu Z, Zhou H, et al. LincRNA00907 promotes NASH progression by targeting miRNA-942-5p\/TAOK1. Aging (Albany NY). 2024;16(8):6868\u201382.","journal-title":"Aging (Albany NY)"},{"key":"714_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-025-02315-8","author":"Q Gao","year":"2025","unstructured":"Gao Q, Bao M, Tan J, Zhang H, Fan L, Zhou Y, et al. Copy number loss of APP cause thoracic aortic dissection. Hypertens Res. 2025. https:\/\/doi.org\/10.1038\/s41440-025-02315-8.","journal-title":"Hypertens Res"},{"key":"714_CR13","unstructured":"Chen QL, Xie CF, Feng KL, Cui DY, Sun SL, Zhang JC, et al. Erratum: microRNAs carried by exosomes promote epithelial-mesenchymal transition and metastasis of liver cancer cells. American journal of translational research. 2021;13(2):812."},{"key":"714_CR14","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5646","author":"A Li","year":"2024","unstructured":"Li A, Xie J, Lv L, Zheng Z, Yang W, Zhuo W, et al. RPL9 acts as an oncogene by shuttling miRNAs through exosomes in human hepatocellular carcinoma cells. Int J Oncol. 2024;64(6):58. https:\/\/doi.org\/10.3892\/ijo.2024.5646","journal-title":"Int J Oncol"},{"key":"714_CR15","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.2147\/CMAR.S249582","volume":"12","author":"QL Shan","year":"2020","unstructured":"Shan QL, Chen NN, Meng GZ, Qu F. Overexpression of lncRNA MT1JP mediates apoptosis and migration of hepatocellular carcinoma cells by regulating miR-24-3p. Cancer Manag Res. 2020;12:4715\u201324.","journal-title":"Cancer Manag Res"},{"issue":"10","key":"714_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/apt.17506","volume":"57","author":"A Barnard Giustini","year":"2023","unstructured":"Barnard Giustini A, Ioannou GN, Sirlin C, Loomba R. Review article: available modalities for screening and imaging diagnosis of hepatocellular carcinoma-current gaps and challenges. Aliment Pharmacol Ther. 2023;57(10):1056\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"714_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111224","volume":"136","author":"E Lv","year":"2021","unstructured":"Lv E, Sheng J, Yu C, Rao D, Huang W. LncRNA influence sequential steps of hepatocellular carcinoma metastasis. Biomed Pharmacother. 2021;136:111224.","journal-title":"Biomed Pharmacother"},{"key":"714_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s41065-026-00664-z","author":"T Mu","year":"2026","unstructured":"Mu T, Zhang S, Zhong Y, Zhou Z, Xie L, Zhou Y, et al. Identification and external validation of a prognostic signature based on myeloid-derived suppressor cell-related lncRNAs for hepatocellular carcinoma. Hereditas. 2026. https:\/\/doi.org\/10.1186\/s41065-026-00664-z.","journal-title":"Hereditas"},{"key":"714_CR19","doi-asserted-by":"crossref","unstructured":"Shi Y, Liu JB, Deng J, Zou DZ, Wu JJ, Cao YH, et al. The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma. Hereditas. 2021;158(1):44.","DOI":"10.1186\/s41065-021-00208-7"},{"key":"714_CR20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2147\/JHC.S408800","volume":"10","author":"Q Wei","year":"2023","unstructured":"Wei Q, Liu G, Huang Z, Huang Y, Huang L, Huang Z, et al. LncRNA MEG3 inhibits tumor progression by modulating macrophage phenotypic polarization via miR-145-5p\/DAB2 axis in hepatocellular carcinoma. J Hepatocell Carcinoma. 2023;10:1019\u201335.","journal-title":"J Hepatocell Carcinoma"},{"issue":"6","key":"714_CR21","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1007\/s11033-022-07325-0","volume":"49","author":"Y Hu","year":"2022","unstructured":"Hu Y, Li H, Zhang H, Tang Q, Zhang G, Li X, et al. The long non-coding RNA LIMT inhibits metastasis of hepatocellular carcinoma and is suppressed by EGF signaling. Mol Biol Rep. 2022;49(6):4749\u201357.","journal-title":"Mol Biol Rep"},{"key":"714_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.634690","volume":"9","author":"XM Hu","year":"2021","unstructured":"Hu XM, Li ZX, Lin RH, Shan JQ, Yu QW, Wang RX, et al. Guidelines for regulated cell death assays: a systematic summary, a categorical comparison, a prospective. Front Cell Dev Biol. 2021;9:634690.","journal-title":"Front Cell Dev Biol"},{"key":"714_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100863","author":"Y Li","year":"2024","unstructured":"Li Y, Rasheed M, Liu J, Chen Z, Deng Y. Deciphering the molecular nexus: an in-depth review of mitochondrial pathways and their role in cell death crosstalk. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13100863.","journal-title":"Cells"},{"issue":"2","key":"714_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/jcmm.17126","volume":"26","author":"S Khashkhashi Moghadam","year":"2022","unstructured":"Khashkhashi Moghadam S, Bakhshinejad B, Khalafizadeh A, Mahmud Hussen B, Babashah S. Non-coding RNA-associated competitive endogenous RNA regulatory networks: novel diagnostic and therapeutic opportunities for hepatocellular carcinoma. J Cell Mol Med. 2022;26(2):287\u2013305.","journal-title":"J Cell Mol Med"},{"issue":"11","key":"714_CR25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.7150\/ijms.85253","volume":"20","author":"Q He","year":"2023","unstructured":"He Q, Chen N, Wang X, Li P, Liu L, Rong Z, et al. Prognostic value and immunological roles of GPX3 in gastric cancer. Int J Med Sci. 2023;20(11):1399\u2013416.","journal-title":"Int J Med Sci"},{"key":"714_CR26","doi-asserted-by":"publisher","DOI":"10.21769\/bioprotoc.3586","author":"DM Gau","year":"2020","unstructured":"Gau DM, Roy P. Single cell migration assay using human breast cancer MDA-MB-231 cell line. Bio-protocol. 2020. https:\/\/doi.org\/10.21769\/bioprotoc.3586.","journal-title":"Bio-protocol"},{"issue":"4","key":"714_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10555-023-10120-3","volume":"42","author":"M Janin","year":"2023","unstructured":"Janin M, Davalos V, Esteller M. Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics. Cancer Metastasis Rev. 2023;42(4):1071\u2013112.","journal-title":"Cancer Metastasis Rev"},{"key":"714_CR28","doi-asserted-by":"publisher","unstructured":"Liu L, Jiang H, Pan H, Zhu X. LncRNA XIST promotes liver cancer progression by acting as a molecular sponge of miR-200b-3p to regulate ZEB1\/2 expression. The Journal of international medical research. 2021;49(5):3000605211016211. https:\/\/doi.org\/10.1177\/03000605211016211.\u00a0IF: 1.8 Q3 B4.","DOI":"10.1177\/03000605211016211"},{"issue":"1","key":"714_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0206-y","volume":"5","author":"Z Gao","year":"2020","unstructured":"Gao Z, Zhou L, Hua S, Wu H, Luo L, Li L, et al. MiR-24-3p promotes colon cancer progression by targeting ING1. Signal Transduct Target Ther. 2020;5(1):171.","journal-title":"Signal Transduct Target Ther"},{"key":"714_CR30","doi-asserted-by":"publisher","unstructured":"Jing P, Xie N, Zhao N, Zhu X, Li P, Gao G, et al. miR-24-3p\/KLF8 Signaling Axis Contributes to LUAD Metastasis by Regulating EMT. J Immunol Res. 2020;2020:4036047. https:\/\/doi.org\/10.1155\/2020\/4036047.\u00a0IF: 3.2 Q3 B3.","DOI":"10.1155\/2020\/4036047"},{"issue":"12","key":"714_CR31","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1111\/jphp.13351","volume":"72","author":"V Shah","year":"2020","unstructured":"Shah V, Shah J. Recent trends in targeting miRNAs for cancer therapy. J Pharm Pharmacol. 2020;72(12):1732\u201349.","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"714_CR32","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/mc.23769","volume":"63","author":"S Kuang","year":"2024","unstructured":"Kuang S, Zhang J, Huang N, Zhang J, Chen B, Wang L, et al. The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. Mol Carcinog. 2024;63(9):1738\u201349.","journal-title":"Mol Carcinog"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00714-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00714-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00714-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:26:05Z","timestamp":1792628765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00714-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00714-6","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Changzhou Third People\u2019s Hospital before the study began. The written informed consent has been obtained from the participants involved.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"117"}}